ASTERIAS BIOTHERAPEUTICS, INC.
ASTERIAS BIOTHERAPEUTICS, INC. (AST): 3 pipeline candidates · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
9.6 months
N/A
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for ASTERIAS BIOTHERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.5M
Quarterly Burn
$2.9M
Runway
9.6 mo
Revenue
$116K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in ASTERIAS BIOTHERAPEUTICS, INC.'s pipeline?
ASTERIAS BIOTHERAPEUTICS, INC. (AST) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ASTERIAS BIOTHERAPEUTICS, INC.'s lead drug candidate?
ASTERIAS BIOTHERAPEUTICS, INC.'s most advanced tracked candidate is ast-opc1 (Phase 1) for spinal cord injuries.
What is ASTERIAS BIOTHERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ASTERIAS BIOTHERAPEUTICS, INC. has approximately 9.6 months of cash runway.
Who is the CEO of ASTERIAS BIOTHERAPEUTICS, INC.?
Questcor Pharmaceuticals is the chief executive officer of ASTERIAS BIOTHERAPEUTICS, INC. (AST).
Get the full picture on ASTERIAS BIOTHERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.